AR and prostate carcinoma: The transient orexin receptor pathway activity at 0 h corresponds to OX1R’s dual role in prostate cancer - baseline receptor presence in LNCaP cells (Graybill and Weissig, 2017) with therapeutic potential through androgen receptor translocation inhibition (Graybill and Weissig, 2017; Couvineau et al., 2021).